{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:36:11Z","timestamp":1790429771130,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peptide-major histocompatibility complex class II (pMHCII)-based nanomedicines displaying tissue-specific autoantigenic epitopes can blunt specific autoimmune conditions by re-programming cognate antigen-experienced CD4+ T-cells into disease-suppressing T-regulatory type 1 (TR1) cells. Here, we show that single pMHCII-based nanomedicines displaying epitopes from mitochondrial, endoplasmic reticulum or cytoplasmic antigens associated with primary biliary cholangitis (PBC) or autoimmune hepatitis (AIH) can broadly blunt PBC, AIH and Primary Sclerosing Cholangitis in various murine models in an organ- rather than disease-specific manner, without suppressing general or local immunity against infection or metastatic tumors. Therapeutic activity is associated with cognate TR1 cell formation and expansion, TR1 cell recruitment to the liver and draining lymph nodes, local B-regulatory cell formation and profound suppression of the pro-inflammatory capacity of liver and liver-proximal myeloid dendritic cells and Kupffer cells. Thus, autoreactivity against liver-enriched autoantigens in liver autoimmunity is not disease-specific and can be harnessed to treat various liver autoimmune diseases broadly.<\/jats:p>","DOI":"10.1038\/s41467-019-09893-5","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T10:04:05Z","timestamp":1557828245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-2141","authenticated-orcid":false,"given":"Channakeshava Sokke","family":"Umeshappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiswarup","family":"Singha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa Hebbandi","family":"Nanjundappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-9687","authenticated-orcid":false,"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"9893_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nature16962","volume":"530","author":"X Clemente-Casares","year":"2016","unstructured":"Clemente-Casares, X. et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530, 434\u2013440 (2016).","journal-title":"Nature"},{"key":"9893_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nnano.2017.56","volume":"12","author":"S Singha","year":"2017","unstructured":"Singha, S. et al. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. Nat. Nanotechnol. 12, 701\u2013710 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"9893_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1034\/j.1399-0039.2003.00152.x","volume":"62","author":"S Lieberman","year":"2003","unstructured":"Lieberman, S. & DiLorenzo, T. A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 62, 359\u2013377 (2003).","journal-title":"Tissue Antigens"},{"key":"9893_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.coi.2005.09.014","volume":"17","author":"U Walter","year":"2005","unstructured":"Walter, U. & Santamaria, P. CD8\u2009+\u2009T cells in autoimmunity. Curr. Opin. Immunol. 17, 624\u2013631 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"9893_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/gut.2007.122150","volume":"84","author":"DE Jones","year":"2008","unstructured":"Jones, D. E. Pathogenesis of primary biliary cirrhosis. Postgrad. Med. J. 84, 23\u201333 (2008).","journal-title":"Postgrad. Med. J."},{"key":"9893_CR6","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3748\/wjg.14.3781","volume":"14","author":"JR Hov","year":"2008","unstructured":"Hov, J. R., Boberg, K. M. & Karlsen, T. H. Autoantibodies in primary sclerosing cholangitis. World J. Gastroenterol. 14, 3781\u20133791 (2008).","journal-title":"World J. Gastroenterol."},{"key":"9893_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1740-2557-1-2","volume":"1","author":"K Zachou","year":"2004","unstructured":"Zachou, K., Rigopoulou, E. & Dalekos, G. N. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J. Autoimmune Dis. 1, 2 (2004).","journal-title":"J. Autoimmune Dis."},{"key":"9893_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","volume":"48","author":"A Floreani","year":"2015","unstructured":"Floreani, A. et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin. Rev. Allergy Immunol. 48, 192\u2013197 (2015).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"9893_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1084\/jem.20051911","volume":"203","author":"J Irie","year":"2006","unstructured":"Irie, J. et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J. Exp. Med. 203, 1209\u20131219 (2006).","journal-title":"J. Exp. Med."},{"key":"9893_CR10","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/hep.20642","volume":"41","author":"AJ Robe","year":"2005","unstructured":"Robe, A. J., Kirby, J. A., Jones, D. E. & Palmer, J. M. A key role for autoreactive B cells in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology 41, 1106\u20131112 (2005).","journal-title":"Hepatology"},{"key":"9893_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/JCI0214698","volume":"109","author":"H Kita","year":"2002","unstructured":"Kita, H. et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J. Clin. Invest. 109, 1231\u20131240 (2002).","journal-title":"J. Clin. Invest."},{"key":"9893_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1172\/JCI4213","volume":"102","author":"S Shimoda","year":"1998","unstructured":"Shimoda, S. et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J. Clin. Invest. 102, 1831\u20131840 (1998).","journal-title":"J. Clin. Invest."},{"key":"9893_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares, A., Caballeria, L. & Rodes, J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130, 715\u2013720 (2006).","journal-title":"Gastroenterology"},{"key":"9893_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/hep.28641","volume":"64","author":"HR Bae","year":"2016","unstructured":"Bae, H. R. et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 64, 1189\u20131201 (2016).","journal-title":"Hepatology"},{"key":"9893_CR15","doi-asserted-by":"publisher","first-page":"e79580","DOI":"10.1371\/journal.pone.0079580","volume":"8","author":"B Qin","year":"2013","unstructured":"Qin, B. et al. Association of human leukocyte antigen class II with susceptibility to primary biliary cirrhosis: a systematic review and meta-analysis. PLoS ONE 8, e79580 (2013).","journal-title":"PLoS ONE"},{"key":"9893_CR16","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.4049\/jimmunol.1202445","volume":"190","author":"IT Chow","year":"2013","unstructured":"Chow, I. T. et al. Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08:01 and DRB1*11:01 Is predicted by their structural motifs and correlates with disease risk. J. Immunol. 190, 4516\u20134524 (2013).","journal-title":"J. Immunol."},{"key":"9893_CR17","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jhep.2014.02.006","volume":"60","author":"P Fickert","year":"2014","unstructured":"Fickert, P. et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J. Hepatol. 60, 1290\u20131303 (2014).","journal-title":"J. Hepatol."},{"key":"9893_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jaut.2009.08.010","volume":"34","author":"MS Longhi","year":"2010","unstructured":"Longhi, M. S., Ma, Y., Mieli-Vergani, G. & Vergani, D. Aetiopathogenesis of autoimmune hepatitis. J. Autoimmun. 34, 7\u201314 (2010).","journal-title":"J. Autoimmun."},{"key":"9893_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/hep.26380","volume":"58","author":"M Hardtke-Wolenski","year":"2013","unstructured":"Hardtke-Wolenski, M. et al. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4\u2009+\u2009T cells. Hepatology 58, 718\u2013728 (2013).","journal-title":"Hepatology"},{"key":"9893_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1055\/s-0036-1597929","volume":"37","author":"A Pares","year":"2017","unstructured":"Pares, A. Novel treatment strategies for primary biliary cholangitis. Semin. Liver Dis. 37, 60\u201372 (2017).","journal-title":"Semin. Liver Dis."},{"key":"9893_CR21","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/NEJMra1506330","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis, K. N. & LaRusso, N. F. Primary sclerosing cholangitis. N. Engl. J. Med. 375, 2501\u20132502 (2016).","journal-title":"N. Engl. J. Med."},{"key":"9893_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/gast.2001.25542","volume":"121","author":"P Fickert","year":"2001","unstructured":"Fickert, P. et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121, 170\u2013183 (2001).","journal-title":"Gastroenterology"},{"key":"9893_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4049\/jimmunol.1001597","volume":"186","author":"GX Yang","year":"2011","unstructured":"Yang, G. X. et al. CD8 T cells mediate direct biliary ductule damage in nonobese diabetic autoimmune biliary disease. J. Immunol. 186, 1259\u20131267 (2011).","journal-title":"J. Immunol."},{"key":"9893_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696\u2013699 (1995).","journal-title":"J. Hepatol."},{"key":"9893_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","volume":"127","author":"P Fickert","year":"2004","unstructured":"Fickert, P. et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127, 261\u2013274 (2004).","journal-title":"Gastroenterology"},{"key":"9893_CR26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jhep.2015.06.008","volume":"63","author":"EM de Vries","year":"2015","unstructured":"de Vries, E. M. et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J. Hepatol. 63, 1212\u20131219 (2015).","journal-title":"J. Hepatol."},{"key":"9893_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1465-9921-9-57","volume":"9","author":"MD Tate","year":"2008","unstructured":"Tate, M. D., Brooks, A. G. & Reading, P. C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir. Res. 9, 57 (2008).","journal-title":"Respir. Res."},{"key":"9893_CR28","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.4049\/jimmunol.181.10.6829","volume":"181","author":"MA Otten","year":"2008","unstructured":"Otten, M. A. et al. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181, 6829\u20136836 (2008).","journal-title":"J. Immunol."},{"key":"9893_CR29","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1046\/j.1365-2168.2002.02183.x","volume":"89","author":"EA te Velde","year":"2002","unstructured":"te Velde, E. A. et al. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br. J. Surg. 89, 1302\u20131309 (2002).","journal-title":"Br. J. Surg."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09893-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T23:35:29Z","timestamp":1671233729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09893-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["9893"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-09893-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P. Santamaria is Scientific Founder of Parvus Therapeutics, Inc. and has a financial interest in the company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2150"}}